Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Spark's Vision Loss Gene Therapy Raises US FDA Questions About Novel Endpoint

Oct 11 2017

• By Sue Sutter

Eye

Related Content

Spark Therapeutics' Vision Loss Gene Therapy Gets FDA Panel Review

Aug 28 2017

Novartis CAR-T Therapy's Swift Approval Aided By REMS And New US FDA Review Model

Aug 31 2017

Novartis CAR-T Site Selection, Risk Management Are Model For Other Sponsors

Jul 13 2017

Related Companies

Spark Therapeutics, Inc.

Novartis AG

Additional Topics

United States Advisory Committees Drug Review Regenerative Medicine Regulation BioPharmaceutical Ophthalmic

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.